NO answer to Alzheimer's disease?

Circulation Research

Volumn 107, Issue 12, 2010, Pages 1400-1402

  Chu, Yi ^a   Heistad, Donald D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Alzheimer's disease; endothelium; nitric oxide

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; CAMP RESPONSE ELEMENT BINDING PROTEIN; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AORTA; BRAIN BLOOD VESSEL; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; MOUSE; MULTIINFARCT DEMENTIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN CHEMISTRY; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III;

EID: 78650682351     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.234450     Document Type: Editorial

References (23)

1. Thomas T, Thomas G, McLendon C, Sutton ET, Mullan M. /3-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996; 380:168-171.
2. Thomas T, McLendon C, Sutton ET, Thomas G. Cerebrovascular endothelial dysfunction mediated by beta-amyloid. Neuroreport. 1997;8: 1387-1391. (Pubitemid 27242542)
3. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchel DR, Hsiao KK, Carlson GA. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nature Neurosci. 1999;2:157-161.
4. Niwa K, Carlson GA, Iadecola C. Exogenous A/31-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overex-pression in mice. J Cereb Blood Flow Metab. 2000;20:1659-1668.
5. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010;120:287-296.
6. Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res. 2010;107:1498-1502.
7. De Strooper B. Proteases and proteolysis in Alzheimer's disease: a multifactorial view on the disease process. Physiol Rev. 2010;90:465-494.
8. Son H, Hawkins RD, Martin K, Kiebler M, Huang PL, Fishman MC, Kandel ER. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell. 1996;87: 1015-1023.
9. Kriegsfeld LJ, Eliasson MJ, Demas GE, Blackshaw S, Dawson TM, Nelson RJ, Snyder SH. Nocturnal motor coordination deficits in neuronal nitric oxide synthase knock-out mice. Neuroscience. 1999;89:311-315.
10. Nathan C, Calingasan N, Nezezon J, Ding A, Lucia MS, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NS, Chen J, Vodovotz Y, Kipiani K, Beal MF. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med. 2005;202:1163-1169.
11. Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H. NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:12867-12872.
12. Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP. The effects of NOS2 gene deletion on mice expressing mutated human A/3PP. J Alzheimers Dis. 2008;15:571-587.
13. Dere E, Frisch C, DeSouza Silva MA, Godecke A, Schrader J, Huston JP. Unaltered radial maze performance and brain acetylcholine of the endothelial nitric oxide synthase knockout mouse. Neuroscience. 2001;107:561-570.
14. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010;66:631-645.
15. de la Monte SM, Lu BX, Sohn YK, Etienne D, Kraft J, Ganju N, Wands JR. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging. 2000;21:309-319.
16. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2010;285:27737-27744.
17. Pilz RB, Casteel. Regulation of gene expression by cyclic GMP. Circ Res. 2003;93:1034-1046.
18. Salbaum JM, Weidemann A, Lemaire HG, Masters CL, Beyreuther K. The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J. 1988;7:2807-2813.
19. Pilz RB, Suhasini M, Idriss S, Meinkoth JL, Boss GR. Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J. 1995;9:552-558.
20. Sellak H, Yang X, Cao X, Cornwell T, Soff GA, Lincoln T. Sp1 transcription factor as a molecular target for nitric oxide- and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Ia expression in vascular smooth muscle cells. Circ Res. 2002;90:405-412.
21. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nature Rev Neurosci. 2004;5:347-360.
22. Puzzo D, Staniszewski A, Shi XD, Privitera L, Leznik E, Liu S, Zhang H, Feng Y, Palmeri A, Landry DW, Arancio O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and A/3 load in an Alzheimer's disease mouse model. J Neurosci. 2009;29:8075-8086.
23. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-/3 peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci. 2005;25:6887-6897.